---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-010138"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:36:44.918250+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients

## Summary
- Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.
- Entered $20M equity line with Yorkville in Feb 2025; expects cash runway into Q2 2025.
- Phase 1 Decoy20 weekly dosing cohort >20 patients; early stable disease observed.
- R&D expense Q4 2024 $2.5M vs $2.0M YoY; full-year $7.2M vs $7.6M.
- Clinical supply agreement with BeiGene for tislelizumab combo trial expected in 2025.

## SEC filing metadata
- accession: 0001493152-25-010138
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/0001493152-25-010138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-010138
- JSON: https://secwatch.observer/filing/0001493152-25-010138.json
- Plain text: https://secwatch.observer/filing/0001493152-25-010138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.